The Current Ratio as of December 2024 (TTM) for GlycoMimetics, Inc. (GLYC) is 3.62

According to GlycoMimetics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.62. This represents a change of -33.54% compared to the average of 5.45 of the last 4 quarters.

GlycoMimetics, Inc. (GLYC) Historical Current Ratio (quarterly & annually)

How has GLYC Current Ratio performed in the past?

The mean historical Current Ratio of GlycoMimetics, Inc. over the last ten years is 10.67. The current 3.62 Current Ratio has changed 3.29% with respect to the historical average. Over the past ten years (40 quarters), GLYC's Current Ratio was at its highest in in the September 2018 quarter at 34.57. The Current Ratio was at its lowest in in the September 2024 quarter at 3.62.

GlycoMimetics, Inc. (GLYC) Current Ratio by Quarter and Year

Discovering the peaks and valleys of GlycoMimetics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

GlycoMimetics, Inc. (GLYC) Average Current Ratio

How has GLYC Current Ratio performed in the past?

The current Current Ratio of GlycoMimetics, Inc. (GLYC) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

GlycoMimetics, Inc. (GLYC) Current Ratio vs. Peers

How is GLYC’s Current Ratio compared to its peers?

GlycoMimetics, Inc.’s Current Ratio is less than Mineralys Therapeutics, Inc. (0), less than Foghorn Therapeutics Inc. (8.55), less than Inventiva S.A. (4.77), greater than Dyne Therapeutics, Inc. (0.96), less than aTyr Pharma, Inc. (17.02), less than Trevi Therapeutics, Inc. (6.07), less than Cue Biopharma, Inc. (7.38), greater than AN2 Therapeutics, Inc. (2.22), less than BioAtla, Inc. (9.75), greater than Assembly Biosciences, Inc. (3.11), greater than Spero Therapeutics, Inc. (2.36), greater than Achilles Therapeutics plc (2.68), less than Instil Bio, Inc. (6.04), less than Neoleukin Therapeutics, Inc. (12.90), less than null (15.33),

Build a custom stock screener for GlycoMimetics, Inc. (GLYC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GlycoMimetics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

GlycoMimetics, Inc. (GLYC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like GlycoMimetics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.